Palatin Technologies (PTN)
(Delayed Data from AMEX)
$1.21 USD
-0.07 (-5.47%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.24 +0.03 (2.48%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 121 - 140 ( 202 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Flibanserin Approved; Market''s Ready Willing and Able for BMT
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Entresto''s Success in Heart Failure Should Boost PL-3994''s Visibility
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Path of Stock Doesn''t Jibe With Quality and Depth of Assets; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
AdCom Provides Relief Through Flibanserin; BMT Differentiated Though
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q15 Results; Growing Visibility on BMT and Cardio Programs
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q15 Results; Phase III Rolling and Awaiting Pipeline Developments
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Phase III Gets Going; Expect Success; Tweaking Target to $4
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q15 Results; U.S. Phase III BMT Study To Begin Shortly
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
FY14 Results; U.S. Pivotal Study in BMT Expected to Begin Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Spread the Word, EU Partner On Board; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.